CA3043575A1 - Bmp potentiators - Google Patents

Bmp potentiators Download PDF

Info

Publication number
CA3043575A1
CA3043575A1 CA3043575A CA3043575A CA3043575A1 CA 3043575 A1 CA3043575 A1 CA 3043575A1 CA 3043575 A CA3043575 A CA 3043575A CA 3043575 A CA3043575 A CA 3043575A CA 3043575 A1 CA3043575 A1 CA 3043575A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
disease
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043575A
Other languages
English (en)
French (fr)
Inventor
Jian Ding
Marie-Helene LARRAUFIE
Deborah Rothman
Nik Savage
Shaowen WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3043575A1 publication Critical patent/CA3043575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3043575A 2016-11-10 2017-11-08 Bmp potentiators Abandoned CA3043575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420535P 2016-11-10 2016-11-10
US62/420,535 2016-11-10
PCT/IB2017/056991 WO2018087677A1 (en) 2016-11-10 2017-11-08 Bmp potentiators

Publications (1)

Publication Number Publication Date
CA3043575A1 true CA3043575A1 (en) 2018-05-17

Family

ID=60569967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043575A Abandoned CA3043575A1 (en) 2016-11-10 2017-11-08 Bmp potentiators

Country Status (15)

Country Link
US (2) US10259827B2 (OSRAM)
EP (1) EP3538531A1 (OSRAM)
JP (1) JP2019534302A (OSRAM)
KR (1) KR20190075120A (OSRAM)
CN (1) CN109923118A (OSRAM)
AR (1) AR110163A1 (OSRAM)
AU (1) AU2017357719A1 (OSRAM)
BR (1) BR112019009404A2 (OSRAM)
CA (1) CA3043575A1 (OSRAM)
EA (1) EA201991141A1 (OSRAM)
MX (1) MX2019005504A (OSRAM)
RU (1) RU2019117548A (OSRAM)
TW (1) TW201821076A (OSRAM)
UY (1) UY37477A (OSRAM)
WO (1) WO2018087677A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008824A (es) * 2019-01-23 2021-10-13 Univ Johns Hopkins Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos.
WO2026060005A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy
WO2026059989A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Peripheral blockers for central nervous system-selective drug activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
GR1001225B (el) 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
DE4028677A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028676A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028666A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028675A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028664A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
CA2071332A1 (en) * 1991-06-25 1992-12-26 Laszlo R. Treiber C-21 hydroxylated fk-506 antagonist
GB9202196D0 (en) 1992-02-01 1992-03-18 Fisons Plc Method of treatment
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
GB9218597D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218027D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US7109317B1 (en) * 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000058318A1 (en) 1999-03-31 2000-10-05 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
CA2407259A1 (en) 2000-05-17 2001-11-22 Chaitan Khosla Polyketide derivatives
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200637552A (en) * 2005-01-20 2006-11-01 Array Biopharma Inc Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
WO2015106283A1 (en) * 2014-01-13 2015-07-16 Amplyx Pharmaceuticals, Inc. Antifungal compounds

Also Published As

Publication number Publication date
RU2019117548A (ru) 2020-12-10
KR20190075120A (ko) 2019-06-28
US20190194227A1 (en) 2019-06-27
MX2019005504A (es) 2019-08-12
TW201821076A (zh) 2018-06-16
UY37477A (es) 2018-06-29
EP3538531A1 (en) 2019-09-18
US20180127436A1 (en) 2018-05-10
WO2018087677A1 (en) 2018-05-17
EA201991141A1 (ru) 2019-10-31
JP2019534302A (ja) 2019-11-28
US10259827B2 (en) 2019-04-16
AR110163A1 (es) 2019-02-27
BR112019009404A2 (pt) 2019-07-30
AU2017357719A1 (en) 2019-05-16
CN109923118A (zh) 2019-06-21

Similar Documents

Publication Publication Date Title
CN107108637B (zh) 三唑并嘧啶化合物及其用途
EP3004108B1 (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CN107250108B (zh) 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
CN116354960A (zh) Shp2磷酸酶抑制剂
EP3004112B1 (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EP3810611A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2018130868A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112384220A (zh) sGC刺激剂治疗线粒体障碍的用途
JP2023513797A (ja) Ｕｌｋ１／２阻害剤による単剤療法および併用療法
CA2890692A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
US10259827B2 (en) BMP potentiators
AU2022325819A1 (en) Compounds that inhibit pi3k isoform alpha and methods for treating cancer
MX2012009894A (es) Inhibidores dimericos de iap.
JP2023133571A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
AU2016359438B2 (en) Diamino pyridine derivatives
CN112237579B (zh) 药物组合及其用途
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
JP2022527451A (ja) Ｐｋｍ２モジュレーターおよびその使用方法
HK40039680A (en) Diamino pyridine derivatives
JP2025540906A (ja) Ｒｅｔ－ｌｄｄタンパク質阻害剤
HK40035225A (en) Pharmaceutical combination and use thereof
HK1253530B (en) Diamino pyridine derivatives
NZ613707B2 (en) Purine Derivatives and Pharmaceutically Acceptable salts thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220510